SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2017 / Cilt: 3 - Sayı: 2

The Relationship Between Plasma sTRAIL Level and Disease Activity in Rheumatoid Arthritis

Romatoid Artritte Plazma sTRAIL Düzeyi ile Hastalık Aktivitesi İlişkisi

Funda ERBASAN
Veli YAZISIZ
Münevver KAHRAMAN
Ender TERZİOĞLU
Pages
95–100
Publication Date
2017-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that sTRAIL may have an important role in the pathogenesis of rheumatoid arthritis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to investigate the plasma soluble tumour necrosis factor related apoptosis-inducing ligand sTRAIL level in rheumatoid arthritis RA and to evaluate the relationship between sTRAIL and disease activity.
📊
Key Findings & Data:Material and Methods: 19 RA patients, and as a control group 31 primary Sjogren’s syndrome pSS patients and 24 healthy subjects were included in the study.
💡
Conclusion & Impact:These findings suggest that sTRAIL may have an important role in the pathogenesis of rheumatoid arthritis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:TNF ilişkili apoptoz tetikleyici ligand · Romatoid artrit · Sjögren sendromu

Abstract

Objective: The purpose of this study was to investigate the plasma soluble tumour necrosis factor related apoptosis-inducing ligand sTRAIL level in rheumatoid arthritis RA and to evaluate the relationship between sTRAIL and disease activity. Material and Methods: 19 RA patients, and as a control group 31 primary Sjogren’s syndrome pSS patients and 24 healthy subjects were included in the study. Disease activity of RA patients was calculated by the Disease Activity Score-28 DAS-28 . Plasma sTRAIL concentrations were measured by the enzyme linked immunosorbent assay ELISA .Results: Mean plasma sTRAIL concentration in RA patients 1751 ± 635 pg/ml was higher than in disease control patients with pSS 1234 ± 625 pg/ml and in healthy controls 1181 ± 304 pg/ml p=0.002 . In RA patients, there was no correlation between mean DAS-28 score and plasma sTRAIL levels. And also, there was no correlation between sTRAIL levels and laboratory parameters indicating disease activity such as the erythrocyte sedimentation rate ESR and C-reactive protein CRP . conclusion: Plasma sTRAIL levels were significantly higher in RA regardless of disease activity. These findings suggest that sTRAIL may have an important role in the pathogenesis of rheumatoid arthritis

Özet

Amaç: Çalışmanın amacı romatoid artritte plazmada çözünmüş TNF ilişkili apoptoz tetikleyici ligand sTRAIL düzeyinin saptanması ve sTRAIL düzeyinin hastalık aktivitesi ile ilişkisinin araştırılmasıdır. Gereç ve Yöntemler: 19 Romatoid artrit RA hastası ve kontrol grubu olarak belirlenen 31 primer Sjögren sendromu pSS hastası ile 24 sağlıklı kişi çalışmaya dahil edildi. RA hastalarının hastalık aktivitesi, hastalık aktivite skoru-28 DAS-28 ile hesaplandı. Plazma sTRAIL düzeyi immunoenzimatik yöntem ELISA ile ölçüldü. Bulgular: Ortalama sTRAIL düzeyi RA hastalarında 1751 ± 635 pg/ml , pSS hastaları 1234 ± 625 pg/ml ve sağlıklı kontrol 1181 ± 304 pg/ml grubundan daha yüksek olarak ölçüldü p=0.002 . RA hastalarında DAS-28 ve sTRAIL düzeyi arasında bir korelasyon saptanmadı. Ayrıca sTRAIL düzeyi ile hastalık aktivitesini gösteren ESR ve CRP arasında da korelasyon saptanmadı. Sonuç: RA’li hastaların sTRAIL düzeyleri hastalık aktivitesinden bağımsız olarak anlamlı düzeyde artmaktadır. Bu bulgular sTRAIL’in RA patogenezinde önemli bir rol alabileceğini göstermektedir

🔖

Cite This Article

ERBASAN, F., YAZISIZ, V., KAHRAMAN, M., TERZİOĞLU, E. (2017). The Relationship Between Plasma sTRAIL Level and Disease Activity in Rheumatoid Arthritis. Akdeniz Tıp Dergisi, Cilt: 3 - Sayı: 2, 95–100. https://ajindex.com/articles/725704

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford) 2000;39 Suppl 2:3-12
  2. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15
  3. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12
  4. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1998;326:1-16
  5. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicology Letters 2003; 139(2-3):89-97
  6. Monleón I, Martínez-Lorenzo MJ, Monteagudo L, Lasierra P, Taulés M, Iturralde M, Piñeiro A, Larrad L, Alava MA, Naval J, Anel A. Differential secretion of Fas ligandor APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001;167:6736-44
  7. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC. The Apoptotic ligands TRAIL, TWEAK, and fas ligand mediate monocyte death induced by Autologous Lupus T Cells. J Immunol 2002;169:6020-9
  8. Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M, Kayagaki N, Yagita H, Okumura K. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren’s syndrome. Clin Exp Rheumatol 2002;20:791-8
  9. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA. IFNa-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44
  10. Han LH, Sun WS, Ma CH, Zhang LN, Liu SX, Zhang Q, Gao LF, Chen YH. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 2002;8:1077-80
  11. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854-8
  12. Komatsuda A, Wakui H, Iwamoto K, Togashi M, Maki N, Masai R, Hatakeyama T, Sawada K. Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with active systemic lupus erythematosus. Clin Immunol 2007;125:26-9
  13. Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS. Increased expression and release of functiona